{"id":30513,"date":"2025-01-27T11:21:15","date_gmt":"2025-01-27T10:21:15","guid":{"rendered":"https:\/\/ggba.swiss\/ab2-bio-secures-usd-650-million-partnership-with-nippon-shinyaku-for-rare-disease-therapy\/"},"modified":"2025-01-27T11:25:05","modified_gmt":"2025-01-27T10:25:05","slug":"ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/","title":{"rendered":"AB2 Bio conclut un partenariat de USD 650 millions avec Nippon Shinyaku"},"content":{"rendered":"\n<p>Bas\u00e9e \u00e0 l&rsquo;<a href=\"https:\/\/www.epfl-innovationpark.ch\/\">EPFL Innovation Park<\/a> \u00e0 Lausanne, <a href=\"http:\/\/www.ab2bio.com\/en\/home.8.html\">AB2 Bio<\/a> est sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de th\u00e9rapies pour les syndromes hyperinflammatoires induits par l&rsquo;IL-18, une cytokine inflammatoire. <a href=\"http:\/\/www.ab2bio.com\/en\/products.36.html\">Tadekinig alfa<\/a>, le principal candidat th\u00e9rapeutique de la soci\u00e9t\u00e9, r\u00e9pond aux besoins m\u00e9dicaux non satisfaits des patients atteints du syndrome hyperinflammatoire monog\u00e9nique primaire pilot\u00e9 par l&rsquo;IL-18, caus\u00e9 par une mutation du NLRC4 et une d\u00e9ficience en XIAP.<\/p>\n\n\n\n<p>Cette maladie p\u00e9diatrique tr\u00e8s rare entra\u00eene une inflammation s\u00e9v\u00e8re, potentiellement mortelle, qui peut provoquer une d\u00e9faillance de plusieurs organes si elle n&rsquo;est pas trait\u00e9e. Tadekinig alfa, une prot\u00e9ine humaine recombinante de liaison \u00e0 l&rsquo;IL-18, r\u00e9tablit l&rsquo;\u00e9quilibre des niveaux d&rsquo;IL-18, r\u00e9duisant l&rsquo;hyperinflammation et pr\u00e9venant d&rsquo;autres dommages.<\/p>\n\n\n\n<p>Dans le cadre de ce partenariat, <a href=\"https:\/\/www.nippon-shinyaku.co.jp\/english\/\">Nippon Shinyaku<\/a> a obtenu une option de commercialisation exclusive de Tadekinig alfa pour cette indication principale aux \u00c9tats-Unis, y compris dans des territoires tels que Guam, Porto Rico et les \u00celes Vierges am\u00e9ricaines. AB2 Bio conserve les droits pour toutes les autres indications aux \u00c9tats-Unis et dans le monde.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Un avenir prometteur pour Tadekinig Alfa<\/h4>\n\n\n\n<p>L&rsquo;accord pr\u00e9voit un paiement initial de USD 6 millions et des paiements d&rsquo;\u00e9tape suppl\u00e9mentaires pour le d\u00e9veloppement pouvant atteindre USD 150 millions. Les futures \u00e9tapes commerciales et les redevances pourraient porter la valeur totale de l&rsquo;accord \u00e0 USD 650 millions.<\/p>\n\n\n\n<p>\u00bb Ce partenariat permettra d&rsquo;acc\u00e9l\u00e9rer la mise \u00e0 disposition de Tadekinig alfa aux jeunes patients souffrant de cette maladie rare et d\u00e9vastatrice \u00bb, a d\u00e9clar\u00e9 le Dr Djordje Filipovic, CEO d&rsquo;AB2 Bio, dans le communiqu\u00e9 de presse de l&rsquo;entreprise. \u00ab L&rsquo;expertise de Nippon Shinyaku dans la commercialisation de th\u00e9rapies pour les maladies rares sera inestimable \u00bb.<\/p>\n\n\n\n<p>Tadekinig alfa a d\u00e9j\u00e0 d\u00e9montr\u00e9 une preuve de concept clinique dans trois maladies orphelines, a re\u00e7u la d\u00e9signation de m\u00e9dicament orphelin aux \u00c9tats-Unis et en Europe, et d\u00e9tient les d\u00e9signations de Breakthrough Therapy et de maladie rare p\u00e9diatrique aux \u00c9tats-Unis. Ces r\u00e9alisations positionnent le traitement comme un changement potentiel de la donne pour les maladies hyperinflammatoires.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AB2 Bio, une biotech de l&rsquo;EPFL Innovation Park, a sign\u00e9 un accord d&rsquo;option et de licence avec la soci\u00e9t\u00e9 japonaise Nippon Shinyaku pour d\u00e9velopper Tadekinig alfa, un nouveau traitement pour le syndrome hyperinflammatoire monog\u00e9nique primaire pilot\u00e9 par l&rsquo;IL-18. L&rsquo;accord pr\u00e9voit des paiements anticip\u00e9s pouvant atteindre USD 36 millions et un financement par \u00e9tapes pouvant aller jusqu&rsquo;\u00e0 USD 650 millions.<\/p>\n","protected":false},"author":6,"featured_media":30510,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1188,1163,1141,1171,1168],"class_list":["post-30513","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-healthcare-fr-2","tag-medtech-fr-2","tag-personalized-medicine-fr-2","tag-pharma-fr-2","tag-technology-park-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AB2 Bio conclut un partenariat de $650M avec Nippon Shinyaku<\/title>\n<meta name=\"description\" content=\"AB2 Bio a sign\u00e9 un accord d&#039;option et de licence avec la Nippon Shinyaku pour faire progresser son traitement Tadekinig alfa.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AB2 Bio conclut un partenariat de $650M avec Nippon Shinyaku\" \/>\n<meta property=\"og:description\" content=\"AB2 Bio a sign\u00e9 un accord d&#039;option et de licence avec la Nippon Shinyaku pour faire progresser son traitement Tadekinig alfa.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-27T10:21:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-27T10:25:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/AB2-Bio-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"AB2 Bio conclut un partenariat de USD 650 millions avec Nippon Shinyaku\",\"datePublished\":\"2025-01-27T10:21:15+00:00\",\"dateModified\":\"2025-01-27T10:25:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/\"},\"wordCount\":376,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/AB2-Bio-1180x811-1.jpg\",\"keywords\":[\"Biotech\",\"Financing\",\"Healthcare\",\"Medtech\",\"Personalized Medicine\",\"Pharma\",\"Technology Park\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/\",\"name\":\"AB2 Bio conclut un partenariat de $650M avec Nippon Shinyaku\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/AB2-Bio-1180x811-1.jpg\",\"datePublished\":\"2025-01-27T10:21:15+00:00\",\"dateModified\":\"2025-01-27T10:25:05+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"AB2 Bio a sign\u00e9 un accord d'option et de licence avec la Nippon Shinyaku pour faire progresser son traitement Tadekinig alfa.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/AB2-Bio-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/AB2-Bio-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"Le Tadekinig alfa d\u00e9velopp\u00e9 par AB2 Bio offre une nouvelle approche du traitement des syndromes hyperinflammatoires induits par l'IL-18, donnant ainsi de l'espoir aux patients qui ne b\u00e9n\u00e9ficient d'aucune norme de soins actuelle. | \u00a9 AB2 Bio\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AB2 Bio conclut un partenariat de USD 650 millions avec Nippon Shinyaku\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AB2 Bio conclut un partenariat de $650M avec Nippon Shinyaku","description":"AB2 Bio a sign\u00e9 un accord d'option et de licence avec la Nippon Shinyaku pour faire progresser son traitement Tadekinig alfa.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/","og_locale":"fr_FR","og_type":"article","og_title":"AB2 Bio conclut un partenariat de $650M avec Nippon Shinyaku","og_description":"AB2 Bio a sign\u00e9 un accord d'option et de licence avec la Nippon Shinyaku pour faire progresser son traitement Tadekinig alfa.","og_url":"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-01-27T10:21:15+00:00","article_modified_time":"2025-01-27T10:25:05+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/AB2-Bio-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"AB2 Bio conclut un partenariat de USD 650 millions avec Nippon Shinyaku","datePublished":"2025-01-27T10:21:15+00:00","dateModified":"2025-01-27T10:25:05+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/"},"wordCount":376,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/AB2-Bio-1180x811-1.jpg","keywords":["Biotech","Financing","Healthcare","Medtech","Personalized Medicine","Pharma","Technology Park"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/","url":"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/","name":"AB2 Bio conclut un partenariat de $650M avec Nippon Shinyaku","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/AB2-Bio-1180x811-1.jpg","datePublished":"2025-01-27T10:21:15+00:00","dateModified":"2025-01-27T10:25:05+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"AB2 Bio a sign\u00e9 un accord d'option et de licence avec la Nippon Shinyaku pour faire progresser son traitement Tadekinig alfa.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/AB2-Bio-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/AB2-Bio-1180x811-1.jpg","width":1180,"height":811,"caption":"Le Tadekinig alfa d\u00e9velopp\u00e9 par AB2 Bio offre une nouvelle approche du traitement des syndromes hyperinflammatoires induits par l'IL-18, donnant ainsi de l'espoir aux patients qui ne b\u00e9n\u00e9ficient d'aucune norme de soins actuelle. | \u00a9 AB2 Bio"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/ab2-bio-conclut-un-partenariat-de-usd-650-millions-avec-nippon-shinyaku\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"AB2 Bio conclut un partenariat de USD 650 millions avec Nippon Shinyaku"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/30513","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=30513"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/30513\/revisions"}],"predecessor-version":[{"id":30515,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/30513\/revisions\/30515"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/30510"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=30513"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=30513"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=30513"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}